Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.79 Insider Own0.30% Shs Outstand211.68M Perf Week0.88%
Market Cap14.49B Forward P/E32.55 EPS next Y2.10 Insider Trans-11.36% Shs Float211.18M Perf Month9.30%
Income-167.20M PEG- EPS next Q0.24 Inst Own96.80% Short Float3.25% Perf Quarter-21.82%
Sales1.53B P/S9.44 EPS this Y-385.10% Inst Trans-0.54% Short Ratio2.66 Perf Half Y-30.88%
Book/sh7.69 P/B8.90 EPS next Y91.44% ROA-7.80% Target Price82.31 Perf Year-50.56%
Cash/sh5.53 P/C12.37 EPS next 5Y31.09% ROE-11.10% 52W Range60.22 - 140.11 Perf YTD-27.75%
Dividend- P/FCF731.58 EPS past 5Y-35.00% ROI-14.80% 52W High-51.16% Beta0.72
Dividend %- Quick Ratio3.80 Sales past 5Y38.90% Gross Margin94.60% 52W Low13.62% ATR1.88
Employees1208 Current Ratio3.90 Sales Q/Q-0.50% Oper. Margin-11.60% RSI (14)50.73 Volatility2.25% 2.70%
OptionableYes Debt/Eq0.01 EPS Q/Q79.70% Profit Margin-10.90% Rel Volume0.53 Prev Close66.67
ShortableYes LT Debt/Eq0.01 EarningsMay 01 BMO Payout- Avg Volume2.58M Price68.43
Recom2.20 SMA205.63% SMA50-4.49% SMA200-28.98% Volume1,372,984 Change2.64%
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Apr-05-18Reiterated Barclays Overweight $165 → $135
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Apr-17-17Downgrade Piper Jaffray Overweight → Neutral
Apr-10-17Initiated Gabelli & Co Buy $185
Apr-07-17Reiterated Barclays Overweight $135 → $185
Apr-05-17Downgrade Raymond James Outperform → Mkt Perform
Apr-04-17Reiterated RBC Capital Mkts Outperform $138 → $157
Mar-09-17Initiated UBS Neutral $140
Mar-02-17Initiated Instinet Buy $148
Feb-15-17Reiterated RBC Capital Mkts Outperform $123 → $138
May-26-18 11:07AM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-24-18 08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
07:33AM  Jim Cramer Gives His Opinion On Blue Apron, Teva And More Benzinga
May-23-18 07:02PM  Cramer's lightning round: I don't have a thesis for Blue ... CNBC Videos
May-12-18 09:28AM  Is Agenus Inc. (AGEN) a Buy? Motley Fool
May-10-18 05:50PM  Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs American City Business Journals
07:55AM  Detailed Research: Economic Perspectives on Voya Financial, Dominion Energy, Incyte, MeetMe, Ventas, and Select Medical What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-08-18 12:56AM  Insider Buying Roundup: Elon Musk Buys Tesla (TSLA) Shares After Earnings Call Backlash Insider Monkey
May-07-18 03:59AM  Edited Transcript of INCY earnings conference call or presentation 1-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-01-18 03:24PM  Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates Zacks
10:13AM  Biotech: Better Luck Next Time Barrons.com
09:08AM  Incyte (INCY) Reports A Loss in Q1 Zacks
07:00AM  Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs Business Wire
Apr-30-18 08:18PM  Edited Transcript of INCY earnings conference call or presentation 15-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
10:11AM  Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks
09:20AM  Google's Alphabet Median Pay Close To $200K Investopedia
08:50AM  Should You Sell Incyte (INCY) Before Earnings? Zacks
Apr-27-18 09:48AM  Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1? Zacks
Apr-26-18 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Apr-25-18 05:38PM  Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting Business Wire
10:33AM  Lessons to Learn From April's Biotech Blowups Motley Fool
08:30AM  Today's Research Reports on Trending Tickers: Allergan and Incyte Corporation ACCESSWIRE
Apr-24-18 11:59AM  Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug TheStreet.com -8.50%
07:30AM  Eli Lilly, Incyte shares drop after mixed FDA drug recommendation MarketWatch
07:03AM  Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback CNBC
Apr-23-18 08:10PM  FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis PR Newswire
06:44PM  FDA panel against higher dose of Lilly-Incyte arthritis drug Reuters
05:01PM  FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug Reuters
Apr-20-18 10:54AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY) PR Newswire
08:03AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Apr-19-18 05:27PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY PR Newswire
02:09PM  Eli Lilly's Blockbuster Resurrection Story Has Holes Bloomberg
02:01PM  Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug MarketWatch
09:10AM  Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug MarketWatch
08:15AM  FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug Reuters
Apr-16-18 05:01PM  What Incyte's Phase 3 Fail Means for Immuno-Oncology Motley Fool
04:21PM  NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure Investor's Business Daily
04:16PM  What's Next for Incyte? Motley Fool
08:48AM  NewLink shares fall on late-stage trial changes MarketWatch
08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 06:01PM  What Happened With Incyte's IDO Inhibitor Flop Motley Fool
09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
08:00AM  Incyte to Report First Quarter Financial Results Business Wire
Apr-12-18 06:00PM  Why One Drug Flop Tanked Incyte's Stock Motley Fool +5.34%
05:38PM  The Biggest Movers: Incyte Excites; L Brands Slides Barrons.com
04:37PM  Why GoPro, Incyte, and Wynn Resorts Jumped Today Motley Fool
11:48AM  3 Biotech Stocks Analysts Have Been Too Bullish On Investopedia
Apr-11-18 10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
08:17AM  Is Beaten-Down Incyte Corporation Stock a Buy Now? Motley Fool
06:00AM  10 Cheap, High-Quality Stocks With Major Growth Catalysts Morningstar
Apr-10-18 02:05PM  MARKETS: Welcome to the low volume, low liquidity algo-driven market Yahoo Finance Video
Apr-09-18 05:24PM  NewLink Shares Plunge After Incyte & Merck's Study Fails Zacks
02:24PM  NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade Benzinga
01:41PM  Incyte Cancer Drug Flop Is Costly and Likely to Be Duplicated Bloomberg
10:29AM  Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial Benzinga
09:48AM  Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Incyte and Merck ACCESSWIRE
Apr-08-18 11:54PM  [$$] Biotech Gets a Reality Check The Wall Street Journal
Apr-06-18 10:57PM  [$$] Incyte Shares Tumble After Cancer Drug Fails in Trial With Mercks Keytruda The Wall Street Journal -22.93%
06:30PM  Incyte's Horrible News Derails a Promising Class of Cancer Drugs Motley Fool
05:09PM  What Happened in the Stock Market Today Motley Fool
04:51PM  The Biggest Movers: Ventas Edges Up; Incyte Plunges Barrons.com
04:34PM  Synchrony, Incyte and Lockheed tumble Associated Press
04:29PM  [$$] Biotech Gets a Reality Check The Wall Street Journal
04:06PM  How Incyte's 'Big Time' Failure With Merck In Melanoma Taints Others Investor's Business Daily
03:59PM  How a Biotech Bummer Sent Nektar Therapeutics Stock South Today Motley Fool
03:44PM  Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful CNBC
03:14PM  NewLink will review clinical programs after Merck, Incyte trial failure MarketWatch
01:54PM  Why Incyte and NewLink Genetics Crashed Today Motley Fool
12:41PM  [$$] Incyte Shares Fall After Cancer Drug Fails in Trial With Merck's Keytruda The Wall Street Journal
11:19AM  Incyte stock plummets following disappointing clinical study results American City Business Journals
11:09AM  Biotech Loses Key Bet to Reignite Growth as Incyte Trial Fails Bloomberg
09:30AM  Stocks to Watch: Incyte, JPMorgan, Boeing, WageWorks The Wall Street Journal
09:14AM  NewLink Genetics shares plummet 39% after Merck, Incyte trial failure MarketWatch
08:04AM  Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment MarketWatch
08:03AM  [$$] Incyte slumps 19% after combo therapy fails late-stage test Financial Times
07:44AM  Incyte's combo therapy for skin cancer fails in late-stage study Reuters
07:30AM  Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma Business Wire
Apr-05-18 06:00AM  4 Biotechs Ready for Big Rebounds Investopedia
Apr-02-18 06:33AM  Are Short-Sellers Right About Geron Corporation? Motley Fool
Mar-30-18 02:12PM  10 Deceptively Bad Stocks to Sell Before Youre Pranked InvestorPlace
Mar-29-18 08:45AM  Incyte Could Have a Problem (or 2!) on Its Hands Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Idera Pharmaceuticals and Incyte ACCESSWIRE
Mar-28-18 06:04AM  3 Biotechs That Could Get Big Boosts in April Motley Fool
Mar-27-18 07:00AM  Free Post Earnings Research Report: Incytes Quarterly Sales 36% Surged ACCESSWIRE
Mar-19-18 04:19AM  Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue? Zacks
Mar-18-18 08:47AM  Is Geron Corporation's Stock Set to Sail or Sink? Motley Fool
Mar-15-18 08:35AM  Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018 Business Wire
Mar-09-18 07:12AM  The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte Zacks
Mar-08-18 04:12PM  Top Analyst Reports for Royal Dutch Shell, Mastercard & Itau Unibanco Zacks
08:10AM  Report: Exploring Fundamental Drivers Behind Old Republic International, NiSource, MasTec, Lincoln National, Oceaneering International, and Incyte New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-01-18 01:32PM  NYSE trader: Powell is a straight shooter, unlike Bernanke and Yellen Yahoo Finance Video
Feb-28-18 09:00AM  Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018 Business Wire
Feb-21-18 08:33AM  Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC Zacks
Feb-20-18 12:27PM  Incyte (INCY) Q4 2017 Earnings Conference Call Transcript Motley Fool
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
07:40AM  Wired News - Asterias Biotherapeutics Expands its Global IP Portfolio with New Patents ACCESSWIRE
Feb-19-18 08:23AM  Get Rid of 5 Toxic Stocks or Sell Short for Profit Zacks
Feb-15-18 03:09PM  Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales Zacks
08:58AM  Incyte (INCY) Beats on Sales in Q4 Zacks
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naive acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorMay 02Option Exercise9.9260,000595,20029,267,937May 03 04:19 PM
Hoppenot HerveChairman / CEOMay 02Buy60.9415,000914,100276,690May 03 05:05 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Option Exercise17.7980,0001,423,200107,267May 02 05:04 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Sale62.4380,0004,994,40033,367May 02 05:04 PM
BROOKE PAUL ADirectorApr 05Option Exercise9.9220,000198,400217,859Apr 09 05:01 PM
GRYSKA DAVID WExecutive Vice President, CFOFeb 21Sale85.561,952167,01310,970Feb 22 04:46 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 21Sale85.551,958167,50735,183Feb 22 04:23 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Option Exercise83.836,760566,69120,752Jan 09 04:09 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Sale98.876,760668,36113,992Jan 09 04:09 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Option Exercise72.865,000364,30013,676Jan 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Sale97.265,000486,3008,676Jan 03 04:32 PM
Huber Reid MEVP, Chief Scientific OfficerDec 01Sale98.0169668,21538,205Dec 05 04:01 PM
FRIEDMAN PAUL ADirectorNov 16Sale105.2428,5073,000,077269,011Nov 20 04:25 PM
GRYSKA DAVID WExecutive Vice President, CFONov 02Sale105.633,915413,54113,992Nov 03 04:01 PM
Hoppenot HerveChairman / CEOSep 18Sale119.4570,5028,421,464299,004Sep 20 04:28 PM
Flannelly Barry PEVP & General Manager USSep 14Sale124.2571488,71514,782Sep 15 04:11 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy132.00100,00013,200,00029,247,347Sep 08 05:06 PM
Trower PaulPrincipal Accounting OfficerSep 05Option Exercise17.793,00053,37014,853Sep 07 04:04 PM
Trower PaulPrincipal Accounting OfficerSep 05Sale138.413,000415,23011,853Sep 07 04:04 PM
Siegel Eric H.EVP, General CounselSep 01Option Exercise64.551,820117,48123,553Sep 05 04:27 PM
Siegel Eric H.EVP, General CounselSep 01Sale137.401,820250,06821,733Sep 05 04:27 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Option Exercise17.7920,000355,80055,067Sep 05 04:22 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Sale140.0020,0002,800,00035,067Sep 05 04:22 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Option Exercise89.522,111188,97420,276Aug 31 04:13 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Sale125.002,111263,87518,165Aug 31 04:13 PM
Trower PaulPrincipal Accounting OfficerAug 04Option Exercise17.793,00053,37014,853Aug 07 04:33 PM
Trower PaulPrincipal Accounting OfficerAug 04Sale125.253,000375,75011,853Aug 07 04:33 PM
Siegel Eric H.EVP, General CounselAug 01Option Exercise64.551,820117,48123,553Aug 03 04:54 PM
Siegel Eric H.EVP, General CounselAug 01Sale132.921,820241,91421,733Aug 03 04:54 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Option Exercise85.686,485555,64124,650Jul 21 04:01 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Sale131.096,485850,11918,165Jul 21 04:01 PM
Trower PaulPrincipal Accounting OfficerJul 05Option Exercise17.793,00053,37015,148Jul 07 05:02 PM
Trower PaulPrincipal Accounting OfficerJul 05Sale126.183,000378,54012,148Jul 07 05:02 PM
Siegel Eric H.EVP, General CounselJul 03Option Exercise64.551,820117,48120,036Jul 05 06:20 PM
Siegel Eric H.EVP, General CounselJul 03Sale126.201,820229,68418,216Jul 05 06:20 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Option Exercise73.2159943,85319,614Jul 05 04:12 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Sale129.7459977,71419,015Jul 05 04:12 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Option Exercise91.459,883903,82424,531Jun 22 04:29 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Sale125.009,8831,235,37514,648Jun 22 04:29 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Option Exercise73.2116,7561,226,70735,771Jun 14 04:50 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Sale116.6016,7561,953,75019,015Jun 14 04:50 PM
Siegel Eric H.EVP, General CounselJun 06Option Exercise66.661,29286,12718,216Jun 07 04:21 PM
Trower PaulPrincipal Accounting OfficerJun 05Option Exercise17.793,00053,37013,950Jun 07 04:12 PM
Trower PaulPrincipal Accounting OfficerJun 05Sale132.503,000397,50010,950Jun 07 04:12 PM
Siegel Eric H.EVP, General CounselJun 01Option Exercise64.551,820117,48118,744Jun 02 04:22 PM
Siegel Eric H.EVP, General CounselJun 01Sale130.001,820236,60016,924Jun 02 04:22 PM
BIENAIME JEAN JACQUESDirectorMay 31Buy131.8050065,9004,677Jun 02 04:14 PM